Literature DB >> 19570490

Nonpharmacological approaches for the treatment of urological chronic pelvic pain syndromes in men.

Jeannette M Potts1.   

Abstract

Chronic nonbacterial prostatitis, or urological chronic pelvic pain syndrome (UCPPS), remains a common and often challenging disorder to evaluate and treat. Employing a more holistic approach, including urological therapy, physical therapy, and psychosocial perspectives, may be more appropriate for most patients. Growing evidence supports the use of biofeedback, myofascial trigger point release, prescribed exercise regimens, relaxation techniques, and supportive counseling to treat men with UCPPS.

Entities:  

Mesh:

Year:  2009        PMID: 19570490     DOI: 10.1007/s11934-009-0047-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  27 in total

1.  Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Dean A Tripp; J Curtis Nickel; Yanlin Wang; Mark S Litwin; Mary McNaughton-Collins; J Richard Landis; Richard B Alexander; Anthony J Schaeffer; Michael P O'Leary; Michel A Pontari; Jackson E Fowler; Leroy M Nyberg; John W Kusek
Journal:  J Pain       Date:  2006-10       Impact factor: 5.820

2.  Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells.

Authors:  Y Aoki; P N Kao
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome.

Authors:  J Q Clemens; R B Nadler; A J Schaeffer; J Belani; J Albaugh; W Bushman
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

4.  Psychological and physical factors involved in chronic idiopathic prostatitis.

Authors:  J P Berghuis; J R Heiman; I Rothman; R E Berger
Journal:  J Psychosom Res       Date:  1996-10       Impact factor: 3.006

5.  Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis.

Authors:  H F Galley; S J Nelson; A M Dubbels; N R Webster
Journal:  Crit Care Med       Date:  1997-08       Impact factor: 7.598

Review 6.  Role of alpha-blockers in type III prostatitis: a systematic review of the literature.

Authors:  Vibhash C Mishra; John Browne; Mark Emberton
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

7.  A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome.

Authors:  Steven A Kaplan; Michael A Volpe; Alexis E Te
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

8.  Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes.

Authors:  Mary P FitzGerald; Rodney U Anderson; Jeannette Potts; Christopher K Payne; Kenneth M Peters; J Quentin Clemens; Rhonda Kotarinos; Laura Fraser; Annemarie Cosby; Carole Fortman; Cynthia Neville; Suzanne Badillo; Lisa Odabachian; Andrea Sanfield; Betsy O'Dougherty; Rick Halle-Podell; Liyi Cen; Shannon Chuai; J Richard Landis; Keith Mickelberg; Ted Barrell; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2009-06-17       Impact factor: 7.450

Review 9.  Psychosomatic syndromes, somatization and somatoform disorders.

Authors:  R Kellner
Journal:  Psychother Psychosom       Date:  1994       Impact factor: 17.659

Review 10.  Sexual dysfunction and prostatitis.

Authors:  Hossein Sadeghi-Nejad; Allen Seftel
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 2.862

View more
  1 in total

1.  Long-term effect of extracorporeal shock wave therapy on the treatment of chronic pelvic pain syndrome due to non bacterial prostatitis.

Authors:  Amir Moayednia; Saeid Haghdani; Saeid Khosrawi; Elham Yousefi; Babak Vahdatpour
Journal:  J Res Med Sci       Date:  2014-04       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.